SSY Group (HKG:2005) said it has received drug production and registration approval from China's National Medical Products Administration for its 4mg Tolterodine Tartrate sustained-release capsules, according to a Friday Hong Kong bourse filing.

The product, classified as a type 4 chemical drug and deemed to have passed consistency evaluation, is used for managing overactive bladder, the filing said.